<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040036</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Vasoprotective effects of statins and angiotensin ii blockers in atherothrombosis</dc:title>
<dc:description xml:lang="en">Cardiovascular disease, including atherothrombosis, is the most frequent causeof mortality in the Western World. In the last years, major advances have beenmade in the pathogenesis of this disease. Currently, the drugs most widely usedare the inhibitors of the HMG-CoA reductase (statins) and the antihypertensivedrugs, mainly angiotensin II blockers. The first group has been shown to be effectiveon cardiovascular disease due to atherothrombosis, and the second groupon hypertensive disease. Nevertheless, recent data suggest that these two situationscan improve with the concomitant use of both drugs</dc:description>
<dc:creator>Egido, J</dc:creator>
<dc:creator>Blanco-Colio, L. M</dc:creator>
<dc:creator>Martín-Ventura, J. L</dc:creator>
<dc:creator>Ruiz-Ortega, M</dc:creator>
<dc:creator>Muñoz-García, B</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad vascular, incluyendo la aterotrombosis, es la causa más frecuentede mortalidad en el mundo occidental. En los últimos años se han producido tremendosavances en el mejor conocimiento de la patogenia de esta enfermedad.Sin embargo, el tratamiento farmacológico actual reside en gran medida en la administraciónde inhibidores de la HMG-CoA reductasa (estainas) y los fármacosanti-hipertensivos, principalmente los bloqueantes de la angiotensina II. Los primeroshan demostrado su principal efecto en la enfermedad cardiovascular debidaa aterotrombosis y los segundos en la enfermedad hipertensiva. Sin embargo,datos recientes sugieren que ambas situaciones pueden mejorar con el empleo deambos tipos de fármacos</dc:description>
<dc:source>Nefrologia;25(supl.2): 117-128, jun. 2005. ilus</dc:source>
<dc:identifier>ibc-040036</dc:identifier>
<dc:title xml:lang="es">Efectos vasoprotectores de las estatinas y los bloqueantes de la angiotensina II en la aterotrombosis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d931^s22073</dc:subject>
<dc:subject>^d30300</dc:subject>
<dc:subject>^d8230^s22044</dc:subject>
<dc:subject>^d22334^s22006</dc:subject>
<dc:subject>^d2359^s22057</dc:subject>
<dc:subject>^d22334</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2359^s22044</dc:subject>
<dc:subject>^d22832^s22073</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d2834^s22062</dc:subject>
<dc:subject>^d22891^s22032</dc:subject>
<dc:subject>^d963^s22073</dc:subject>
<dc:subject>^d1166^s22057</dc:subject>
<dc:subject>^d30165^s22073</dc:subject>
<dc:subject>^d2359^s22062</dc:subject>
<dc:subject>^d7152^s22057</dc:subject>
<dc:subject>^d1166^s22032</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200506</dc:date>
</metadata>
</record>
</ibecs-document>
